The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency) for shallow and deep microneedling treatments for patients on a single system.

The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device.

The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency) for shallow and deep microneedling treatments for patients on a single system. The device’s monopolar RF mode delivers energy across a large area of tissue for deep heating and skin tightening through soft tissue coagulation on the face and the body. The bipolar RF mode offers concentrated delivery of energy to treat superficial tissue and rejuvenate skin. The device is also equipped with Tiger Tip technology, semi-insulated needles which allow practitioners to expand the treatment zone and address more tissue per treatment for quicker sessions without sacrificing the epidermis. The device is armed with a single-needle handpiece to target and improve blemishes.

 "Our goal at Cynosure is to provide our customers with revolutionary technologies so they can consistently deliver outstanding results,” says Todd Tillemans, Chief Executive Officer of Cynosure, in a news release. “Potenza takes the microneedling category to a new level by offering unprecedented flexibility for doctors, which translates to personalized treatments and satisfied patients with exceptional outcomes.”

 “Potenza is a highly advanced RF microneedling device with versatility that is unmatched,” adds Dr. Robert Weiss, MD of Maryland Dermatology Laser, Skin and Vein Institute in Hunt Valley, MD. “The device’s four modes allow me to individualize and optimize treatments for my patients who seek out our practice for having the most effective and state-of-the-art technologies."

 Potential side effects include temporary redness, temporary tingling, and burning sensation while receiving treatment.